title: The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease.
abstract: BACKGROUND
  Previously, the inhibition of coronary restenosis with Abciximab (ReoPro)-coated stent in a porcine model was reported. ReoPro inhibits platelet aggregation, the proliferation of vascular smooth muscle cells and the inflammatory reaction.
  
  
  METHODS
  A prospective randomized trial was performed to compare two types of stent for revascularization in the native coronary artery. The primary effective end points were major adverse coronary events (MACE): cardiac death, acute myocardial infarction, target vessel revascularization (TVR) and restenosis at the 6-month clinical and angiographic follow-ups.
  
  
  RESULTS
  One hundred and fifty-five patients were enrolled between August 2001 and June 2003. The mean ages (56.0 +/- 10.0 vs. 56.9 +/- 10.8 years), baseline diameter of stenosis and minimal luminal diameter were no different between the two groups. There was one myocardial infarction and revascularization during the hospital stay in control stent group. During the clinical follow-up there were two myocardial infarctions in control group. Follow-up coronary angiograms were performed in 62.3% (48/77) and 65.4% (51/78) of the coated and control groups, respectively. The diameter of stenosis and late loss were significantly less in the ReoPro-coated stent group compared with the controls (16.4 +/- 5.8% vs. 34.3 +/- 6.1%, p = 0.009; and 0.33 +/- 0.28 mm vs. 0.88 +/- 0.41 mm; p = 0.002). The restenosis and TVR rates of the ReoPro-coated stent were relatively lower compared with the control stent [14.6% (7/48) vs. 29.4% (15/51), p = 0.062; and 9.2% (7/76) vs. 14.7% (11/75); p = 0.327].
  
  
  CONCLUSIONS
  A ReoPro-coated stent is safe, and may be effective in the prevention of coronary restenosis.
authors.affiliation: The Heart Center of Chonnam National University Hospital, Chonnam National University Research Institute of Medical Sciences, Chemical Engineering of Chonnam National University, Gwangju, Korea.
authors.forename: Weon
authors.initials: W
authors.lastname: Kim
authors.forename: Myung Ho
authors.initials: MH
authors.lastname: Jeong
authors.forename: Young Joon
authors.initials: YJ
authors.lastname: Hong
authors.forename: Seng Hyun
authors.initials: SH
authors.lastname: Lee
authors.forename: Woo Seok
authors.initials: WS
authors.lastname: Park
authors.forename: Ju Han
authors.initials: JH
authors.lastname: Kim
authors.forename: In Soo
authors.initials: IS
authors.lastname: Kim
authors.forename: Myung Ja
authors.initials: MJ
authors.lastname: Choi
authors.forename: Young Keun
authors.initials: YK
authors.lastname: Ahn
authors.forename: Jeong Gwan
authors.initials: JG
authors.lastname: Cho
authors.forename: Jong Chun
authors.initials: JC
authors.lastname: Park
authors.forename: Dong Lyun
authors.initials: DL
authors.lastname: Cho
authors.forename: Hoon
authors.initials: H
authors.lastname: Kim
authors.forename: Jung Chaee
authors.initials: JC
authors.lastname: Kang
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000493:pharmacokinetics / Q000627:therapeutic use*; D020099:Coated Materials, Biocompatible / Q000493:pharmacokinetics / Q000627:therapeutic use*; D003324:Coronary Artery Disease / Q000601:surgery*; D023903:Coronary Restenosis / Q000453:epidemiology / Q000517:prevention & control; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use*; D007723:Korea / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D010975:Platelet Aggregation Inhibitors / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000037:antagonists & inhibitors; D011446:Prospective Studies; D015607:Stents
chemical_list: D000911:Antibodies, Monoclonal; D020099:Coated Materials, Biocompatible; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000077284:Abciximab